摘要
目的比较舒肝颗粒与阿立哌唑对首发女性精神分裂症患者药源性高泌乳素血症的疗效与安全性。方法选择收治的药源性高泌乳素血症的首发女性精神分裂症患者180例,按随机数字表法分成对照组和研究组,每组90例。对照组给予阿立哌唑,10 mg/d;研究组给予舒肝颗粒每次1袋,2次/d,共治疗12周。比较2组患者泌乳素(prolactin,PRL)水平,阳性和阴性症状量表(positive and negative syndrome Scale,PANSS),治疗时出现的症状量表(treatment emergent symptom scale,TESS)及不良反应情况。结果 2组患者PRL水平均随治疗时间延长而下降(F_(时间)=9.73,P<0.05),对照组PRL水平下降幅度较研究组大(F_(交互)=4.36,P<0.05),2组患者PRL整体水平差异无统计学意义(F_(分组)=0.13,P>0.05)。2组患者PANSS总分均随治疗时间延长而下降(F_(时间)=23.89,P<0.05);且2组患者PANSS总分下降幅度基本一致(F_(交互)=0.98,P>0.05),2组患者PANSS总分的整体水平差异无统计学意义(F_(分组)=1.06,P>0.05)。2组患者TESS评分随治疗时间延长而上升(F_(时间)=19.56,P<0.05),研究组TESS评分上升幅度较对照组小(F_(交互)=9.16,P<0.05)研究组TESS评分整体水平显著低于对照组(F_(分组)=7.96,P<0.05)。研究组患者治疗4、8、12周不良反应均显著低于对照组(χ~2值分别为4.79、4.84、7.90,P<0.05)。结论舒肝颗粒治疗首发女性精神分裂症患者药源性高泌乳素血症的临床疗效与阿立哌唑疗效相当,不良反应明显少于阿立哌唑,具有更好的安全性。
Objective To compare the therapeutic effects and security of Shugan granule and aripiprazole on drug-induced hyperprolactinemia in women patients with first episode schizophrenia.Methods A total of 180 women patients with first episode schizophrenia combined with drug-induced hyperprolactinemia who were admitted and treated in our hospital were divided into control group(n=90) and research group(n=90) according to the random number table. The patients in control group were treated by aripiprazole 10 mg daily, however,the patients in research group were treated by Shugan granules 1 bag once, twice a day,with a treatment course of 12 weeks for both groups. The prolactin(PRL) levels, positive and negative syndrome scale(PANSS), treatment emergency symptom scale(TESS) and adverse reactions were observed and compared between the two groups.Results The PRL levels in both groups were decreased along with the treatment time extension(F time=9.73, P<0.05). Moreover the decrease extent of PRL level in control group was significantly larger than that in research group(F interaction=4.36, P<0.05). However there were no significant difference in the overall PRL levels between the two groups(F grouping=0.13, P>0.05). The total scores of PANSS in both groups were decreased along with the treatment time extension(F time=23.89, P<0.05). Moreover the decrease extent of PANSS in the two groups were basically similar(F interaction=0.98, P>0.05). In addition there were no significant differences in PANSS scores between the two groups(F grouping=1.06, P>0.05). The TESS scores in both groups were significantly increased along with the treatment time extension(F time=19.56, P<0.05). However the increase extent of TESS scores in research group was significantly lower than that in control group(F interaction=9.16, P<0.05). Moreover the TESS scores in research group were significantly lower than those in control group(F grouping=7.96, P<0.05). After 4-week,8-week,12-week treatment the incidence rates of adverse reactions in research group were significantly lower than those in control group(χ2= 4. 79,4. 84,7. 90,respectively,P < 0. 05). Conclusion The clinical efficacy of Shugan granule in treatment of drug-induced hyperprolactinemia in women patients with first episode schizophrenia is similar to aripiprazole,moreover the side effects and adverse reactions of Shugan granule are significantly less than those of aripiprazole,moreover,the latter has better safety.
作者
周莉
黄朝红
王琦珠
张少川
范广希
胡怡
ZHOU Li;HUANG Chaohong;WANG Qizhu(Yunnan Provincial Mental Hospital, Yunnan,Kunming 650224,China)
出处
《河北医药》
CAS
2019年第9期1304-1307,1312,共5页
Hebei Medical Journal
基金
昆明市卫生科技人才培养项目暨"十百千"工程项目[编号:2017-sw(后备)-65]
昆明市卫生科技人才培养项目暨十百千工程中"昆明市围产期精神障碍诊疗技术中心"项目[编号:2017-(技)-31]
昆明市卫生和计划生育委员会医药卫生科技计划项目(编号:2017-03-09-005)
云南省科技厅-昆明医科大学应用基础研究联合专项项目(编号:201701UH00452)
